Paraproteinemic polyneuropathies in patients with plasma cell neoplasms
https://doi.org/10.58708/2074-2088.2025-1(33)-29-37
Abstract
The main plasma cell neoplasms characterized by the proliferation of clonal plasma cells producing monoclonal immunoglobulin include monoclonal gammopathy of undetermined significance, multiple myeloma, AL amyloidosis, solitary plasmacytoma, lymphoplasmacytic lymphoma, Waldenstrom's macroglobulinemia, primary cold agglutinin disease, heavy chain diseases, plasma cell leukemia, and some paraneoplastic syndromes. Under the influence of monoclonal immunoglobulin on axons or myelin sheath of neurons, a number of patients with plasma cell neoplasms develop paraproteinemic polyneuropathies. They are characterized by a slow course and similar clinical and instrumental manifestations, which complicates their diagnosis and differential diagnosis. This article systematizes the results of current studies devoted to the pathogenesis and clinical features of paraproteinemic polyneuropathies associated with various plasma cell neoplasms.
About the Authors
M. V. Linkou
State Institution "Russian Scientific Research Center for Radiation Medicine and Human Ecology"
Belarus
Belarus
Gomel
Zh. M. Kozich
State Institution "Russian Scientific Research Center for Radiation Medicine and Human Ecology"
Belarus
Belarus
Gomel
N. N. Usova
Gomel State Medical University Educational Institution
Belarus
Belarus
Gomel
References
1. Boccadoro, M. Plasma celldyscrasias: classification, clinical and laboratory characteristics, and differential diagnosis / M. Boccadoro, A. Pileri // Bailliere’s Clinical Haematology. – 1995. – Vol. 8, № 4. – P. 705–719.
2. The 2016 revision of the World Health Organization classification of lymphoid neoplasms / S.H. Swerdlow, E. Campo, S.A. Pileri [et al.] // Blood. – 2016. – Vol. 127, №20. – P. 2375–2390.
3. The 5<sup>th</sup> edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms / R. Alaggio, C. Amador, I. Anagnostopoulos [et al.] // Leukemia. – 2022. – Vol. 36, № 7. – P. 1720–1748.
4. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee / E. Campo, E.S. Jaffe, J.R. Cook [et al.] // Blood. – 2022. – Vol. 140, № 11. – P. 1229–1253.
5. Семочкин, С.В. Плазмоклеточные опухоли в гематологических классификациях 2022 г.: WHO-HAEM5 (ВОЗ, 5-й пересмотр) и ICC (Международная консенсусная классификация). Взгляд клинициста / С.В. Семочкин // Клиническая онкогематология. – 2024. – Т. 17, № 2. – С. 94–108.
6. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma / S.V. Rajkumar, M.A. Dimopoulos, A. Palumbo [et al.] // Lancet Oncol. – 2014. – Vol. 15, №12. – P. 538–548.
7. Множественная миелома. Клинические рекомендации / Л.П. Менделеева, О.М. Вотякова, И.Г. Рехтина [и др.] // Современная Онкология. – 2020. – Т. 22, № 4. – С. 6–28.
8. The prevalence and significance of monoclonal gammopathy of undetermined significance in acute medical admissions / C. Atkin, V. Reddy-Kolanu, M.T. Drayson [et al.] // Br. J. Haematol. – 2020. – Vol. 189, № 6. – P. 1127–1135.
9. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance / R.A. Kyle, D.R. Larson, T.M. Therneau [et al.] // The New England Journal of Medicine. – 2018. – Vol. 378, № 3. – P. 241–249.
10. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma / E. M. Boyle, S. Deshpande, R. Tytarenko [et al.] // Nature Communications. – 2021. – Vol. 293, № 12. – P. 1–13.
11. Prevalence of smoldering multiple myeloma based on nationwide screening / S. Thorsteinsdottir, G.K. Gislason, T. Aspelund [et al.] // Nat Med. – 2023. – Vol. 29, № 2. – P. 467–472.
12. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project / M. D’Agostino, D.A. Cairns, J.J. Lahuerta [et al.] // Journal of Clinical Oncology. – 2022. – Vol. 40, № 29. – P. 3406–3418.
13. Особенности диагностики и лечения различных вариантов плазмоцитомы / В.В. Войцеховский, А.А. Григоренко, Т.В. Есенина [и др.] // Бюллетень физиологии и патологии дыхания. – 2023. – № 88. – С. 105–119.
14. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel / J. Caers, B. Paiva, E. Zamagni [et al.] // Journal of Gematology and Oncology. – 2018. – Vol. 11, № 1. – P. 1–10.
15. Kyle, R.A. A tribute to Jan Gosta Waldenstrom / R.A. Kyle, K.C. Anderson // Blood. – 1997. – Vol. 89, № 12. – P. 4245–4247.
16. Клинико-эпидемиологическая характеристика плазмоклеточных новообразований / Ж.М. Козич, В.Н. Мартинков, И.В. Веялкин [и др.] // Здравоохранение. – 2023. – № 7. – С. 33–42.
17. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting / U. Jager, W. Barcellini, C.M. Broome [et al.] // Blood Reviews. – 2020. – Vol. 41, № 29. – P. 1–22.
18. Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia / Q.A. Hill, R. Stamps, E. Massey [et al.] // British Journal of Haematology. – 2017. – Vol. 177, № 22. – P. 208–220.
19. Immunoglobulin heavy and light chain gene features are correlated with primary cold agglutinin disease onset and activity / A. Malecka, G. Troen, A. Tierens [et al.] // Haematologica. – 2016. – Vol. 101, № 9. – P. 361–364.
20. Roelcke, D. Cold agglutination. Antibodies and antigens / D. Roelcke // Clinical Immunology and Immunopathology. – 1974. – Vol. 2, № 2. – P. 266–280.
21. Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression / M. Basset, K. Hummedah, C. Kimmich [et al.] // Am J Hematol. – 2020. – Vol. 95, № 10. – P. 1158–1169.
22. Plasma cell leukemia : A review of the molecular classification, diagnosis, and evidenced-based treatment / K. Gowin, S. Skerget, J.J. Keats [et al.] // Leukemia Research. – 2021. – № 111. – P. 1–8.
23. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature / P.A. Bardwick, N.J. Zvaifler, G.N. Gill [et al.] // Medicine. – 1980. – Vol. 59, № 4. – P. 311–322.
24. Dispenzieri, A. POEMS syndrome: 2021 Update on diagnosis, risk-stratification, and management / A. Dispenzieri // Am J Hematol. – 2021. – Vol. 96, № 7. – P. 872–888.
25. Левин, О.С. Полиневропатии: Клиническое руководство / О.С. Левин. – 3-е изд., испр. и доп. – М.: ООО «Издательство «Медицинское информационное агентство», 2016. – 480 с.
26. Monoclonal Gammopathy of Undetermined Significance (MGUS) – Not So Asymptomatic after All / O.C. Lomas, T.H. Mouhieddine, S. Tahri [et al.] // Cancers. – 2020. – Vol. 12, № 6. – P. 1–16.
27. From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance / A. Visentin, S. Pravato, F. Castellani [et al.] // Cancers. – 2022. – Vol. 14, № 6. – P. 1–17.
28. Hobbs, M. Waldenström Macroglobulinemia: Clinical Presentation, Diagnosis, and Management / M. Hobbs, A. Fonder, Y. L. HWA // J Adv Pract Oncol. – 2020. – Vol. 11, № 4. – P. 381–389.
29. Efficacy and Safety of Rituximab in Vasculitic Neuropathy : A Systematic Review of the Literature / N. Mena-Vázquez, P. Cabezudo-García, C.F. Varela [et al.] // Reumatol Clin. – 2019. – Vol. 15, № 3. – P. 173–178.
30. Dispenzieri, A. Monoclonal gammopathies of clinical significance / A. Dispenzieri // Hematology. – 2020. – № 1. – P. 380–388.
31. CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell–targeted therapies / M.L. Cann, F. Bouhour, K. Viala [et al.] // Blood. – 2020. – Vol. 136, № 21. – P. 2428–2436.
32. Paraneoplastic Neuropathies: What's New Since the 2004 Recommended Diagnostic Criteria / M. Zoccarato, W. Grisold, A. Grisold [et al.] // Frontiers in Neurology. – 2021. – Vol. 12, № 1. – P. 1–14.
Review
For citations:
Linkou M.V., Kozich Zh.M., Usova N.N. Paraproteinemic polyneuropathies in patients with plasma cell neoplasms. Medical and Biological Problems of Life Activity. 2025;(1):29-37. (In Russ.) https://doi.org/10.58708/2074-2088.2025-1(33)-29-37
Views:
42
Email this article 